Activities

EFSPI International Events

EFSPI/BBS/MSB Modelling & Simulation Sept 2012

Modelling & Simulation and applications to longitudinal data - Programme Agenda

Modelling and simulation in the pharmaceutical industry - reflections from a statistician's perspective - Carl-Fredrick Burman - Astrazeneca

Simplicity, Complexity and Modelling - Stephen Senn - CRP-Santé

The use of modelling and simulation in drug approval - A regulatory view - Norbert Benda - Bfarm

Simulation for Decision Making - MSToolkit for Go/No Go - Chris Campbell - Mango Solutions

A Longitudinal Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy - Benjamin Ribba - INRIA

Using M&S to develop a novel longitudinal Model-based approach for efficacy assessments, with an application to biosimilars in rheumatoid arthritis - Didier Renard - Novartis

Longitudinal analysis at Roche- a Biostatistics and an M&S Perspective - Ulrich Beyer - Cheikh Diack - Roche

Longitudinal analysis at Roche- a Biostatistics and an M&S Perspective - Ulrich Beyer - Cheikh Diack - Roche

REVIEW of Workshop